Predict your next investment

Corporation
HEALTHCARE | Biotechnology
accentia.net

See what CB Insights has to offer

Founded Year

2002

Stage

PIPE | IPO

Total Raised

$16.68M

About Accentia Biopharmaceuticals

Accentia Biopharmaceuticals is a Healthcare/Biotechnology company based in Tampa, Florida. Accentia Biopharmaceuticals' investors include Cantara, RAM Holdings, Pine River Capital Management, Third Coast Capital, Nite Capital Management, Kamunting Street Capital Management, Eagle Asset Management, UBS, Downsview Capital, Bristol Capital Advisors, Whalehaven Capital and SIBEX Capital Fund.

Accentia Biopharmaceuticals Headquarter Location

324 South Hyde Park Avenue Suite 350

Tampa, Florida, 33606,

United States

813-864-2554

Latest Accentia Biopharmaceuticals News

SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Accentia Biopharmaceuticals, Inc. and Certain Officers and Biovest International, Inc. - ABPI and BVTI

Aug 7, 2013

Aug 06, 2013, 17:26 ET from Pomerantz Grossman Hufford Dahlstrom & Gross LLP NEW YORK, Aug. 6, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP has filed a class action lawsuit against Accentia Biopharmaceuticals, Inc.  ("Accentia" or the "Company") (Pink Sheets: ABPI ) and certain of its officers and Biovest International, Inc. ("Biovest") (OTCQB: BVTI), a majority-owned subsidiary of Accentia. The class action, filed in United States District Court, Middle District of Florida, and docketed under 13-CV-2033-T24-AEP, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired securities of Accentia between July 26, 2008 and August 14, 2012 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. If you are a shareholder who purchased Accentia or Biovest securities during the Class Period, you have until September 30, 2013 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased. Accentia acquired an 81% interest in Biovest in June 2003. As of September 30, 2012, Accentia owned approximately 59% of Biovest's outstanding common stock. The BiovaxID vaccine being developed by Biovest is and has been the most important part of Accentia's business and financial prospects. Biovest and Accentia have common management. Biovest is a biotechnology company in the business of developing therapeutic cancer vaccines. Biovest conducted two Phase II clinical trials, and one Phase III clinical trial of BiovaxlD, which was completed in 2008. The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, Defendants made false and/or misleading statements concerning, and/or failed to disclose, among other things:  that the FDA informed Biovest that the results of a Phase III clinical trial for BiovaxID, a potential vaccine for the treatment of non-Hodgkin's lymphoma, did not support an application for approval of BiovaxID. Despite this information, Defendants made numerous statements in press releases and securities filings that gave the misleading impression that the trial results were statistically significant and that Biovest was on track to obtain FDA approval. On August 14, 2012, Biovest issued a press release announcing what it described as a "formal clinical guidance meeting with the U.S. FDA," and disclosed that the FDA required that Biovest conduct a second Phase 3 clinical trial of BiovaxlD. The August 14, 2012 press release identified Biovest as a majority-owned subsidiary of Accentia with Accentia's trading symbol. Also on August 14, 2012, Biovest filed its Form 10-Q with the SEC for the quarter ended June 30, 2012, in which Biovest disclosed that it had met with the FDA and that the FDA had recommended a second Phase 3 clinical trial. On this news, Accentia's shares declined $0.05 cents or 23% percent to close at $0.17 on August 14, 2012 and again on August 15, 2012 shares fell $0.06 cents or 35% to close at $0.11 cents on August 15, 2012. The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com . CONTACT:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Accentia Biopharmaceuticals Patents

Accentia Biopharmaceuticals has filed 5 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/22/2011

3/8/2016

Monoamine oxidase inhibitors, Transcription factors, Aldehydes, Human drug metabolites, Amines

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/22/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/8/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Monoamine oxidase inhibitors, Transcription factors, Aldehydes, Human drug metabolites, Amines

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.